Fooling the Parathyroid Gland - Will There Be Health Benefits?

New England Journal of Medicine

Volumn 350, Issue 15, 2004, Pages 1565-1567

  Curhan, Gary ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PHOSPHATE; VITAMIN D;

CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DIALYSIS; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERPARATHYROIDISM; NAUSEA; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION; VOMITING;

CALCIUM; DRUG THERAPY, COMBINATION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; VITAMIN D;

EID: 1842714907     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048048     Document Type: Editorial

References (15)

1. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol of calcitriol therapy. N Engl J Med 2003;349:446-56.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
4. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
5. Greenland P, LaBree L, Azen SP, Doherty TM, Delxano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5. [Erratum, JAMA 2004;291:563.]
6. Greenland P, LaBree L, Azen SP, Doherty TM, Delxano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-5. [Erratum, JAMA 2004;291:563.]
7. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14. [Erratum, Nephrol Dial Transplant 2000;15:559.]
8. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14. [Erratum, Nephrol Dial Transplant 2000;15:559.]
9. Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999;51:18-26.
10. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
11. Shoback DM, Bilezikian JP, Turner SA, McCary LG, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9.
12. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24.
13. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet hydrochloride for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
14. Moe SM, Sprague SM, Cunningham J, et al. Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HGl. J Am Soc Nephrol 2003;14:463A-464A. abstract.
15. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:Suppl 3:1-201.